Johnson & Johnson

Johnson & Johnson vaccine shown effective against severe COVID-19 illness and variants

Johnson & Johnson expects to share COVID-19 vaccine data next week

Johnson & Johnson confident of March rollout for its COVID-19 vaccine, still aims for 1 billion doses in 2021

Johnson & Johnson ordered to pay $120-million damages in New York baby powder case

Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization

Johnson & Johnson fails to overturn $2.12-billion baby powder verdict, plans U.S. Supreme Court appeal

McKesson says cost of opioid settlements could reach $21-billion

Johnson & Johnson hikes profit forecast, but pause in COVID-19 vaccine trial weighs on shares

The close: Stocks fall amid fresh worries over COVID-19 cases, vaccines

Johnson & Johnson COVID-19 vaccine trial paused as participant’s illness is evaluated

Johnson & Johnson to pay about US$100-million to settle more than 1,000 talc lawsuits: report

Johnson & Johnson kicks off final study of single-shot COVID-19 vaccine in 60,000 volunteers

Johnson & Johnson facing insurance fraud charges in New York over opioid claims

Johnson & Johnson COVID-19 vaccine trial saw some volunteers quit after AstraZeneca scare

Economists question Ottawa’s refusal to release COVID-19 vaccine cost estimates

Johnson & Johnson to begin mid-stage coronavirus vaccine trials in three European countries

Johnson & Johnson to test potential coronavirus vaccine in up to 60,000 volunteers

Johnson & Johnson buying Momenta Pharmaceuticals for around $6.5-billion

U.S. states reportedly seeking $26.4-billion from drug firms in opioid litigation